Innovative Drug Delivery Systems for Alzheimer’s Disease Treatment

Alzheimer’s disease (AD) remains one of the most challenging neurodegenerative disorders with complex pathology and limited therapeutic options. Recent advances in drug delivery systems have opened new avenues for effective treatment by enhancing the bioavailability, targeting, and controlled release of therapeutic agents. This manuscript reviews the evolution of innovative drug delivery systems for Alzheimer’s treatment, including nanotechnology-based carriers, liposomal formulations, polymeric nanoparticles, and intranasal delivery methods. In addition to a comprehensive literature review up to 2017, the study presents a statistical analysis based on preclinical and early clinical trial data and outlines methodologies for evaluating efficacy and safety. The findings suggest that novel drug delivery approaches not only improve the pharmacokinetic profiles of AD drugs but also offer potential in reducing side effects and enhancing targeted delivery across the blood-brain barrier. The study concludes with a discussion on the potential impact, scope, and limitations of these innovative systems in transforming Alzheimer’s disease management.